Xaar

www.xaar.co.uk

Symbol: XAR.L

Currently trading at: 65.75p UP 1.75

Xaar plc was formed in 1990 to acquire, develop and commercially exploit a new digital inkjet printing technology arising out of work done in Cambridge by Cambridge Consultants Ltd. Initial funding came from local and national venture capital funds.

At the time of the acquisition, the IPR consisted of 4 granted patents and 84 patent applications in various jurisdictions. Xaar's business concentrated on licensing these patents and know-how to printer manufacturers primarily for use in office applications. Typical Xaar licensees are multinational corporations who manufacture large volumes of inkjet printheads for use in their own products, or for sale to OEM customers. Xaar has nine printhead licensees including Brother, Konica, Sharp and Toshiba TEC, and two ink licensees, Avecia and Toyo Ink. As a result of further development of the technology by Xaar there are now over 700 patents and patent applications in the Xaar IPR portfolio and the company continues to improve and expand this portfolio.

In October 1997, Xaar completed a successful listing on the London Stock Exchange. In March 1999 the company acquired MIT, an existing licensee, from Pelikan Productktions AG. Xaar's product portfolio has expanded considerably since then and the company now offers a range of digital inkjet printheads and inks. In order to support this augmented product portfolio and the increased demand for its products, Xaar has expanded its sales operations beyond Europe into Asia and the US, setting up offices in Hong Kong and Chicago.

In 2002 the company increased its focus on manufacturing its own range of digital inkjet printheads and relocated all of its manufacturing capability to its Swedish facility, leaving its Cambridge location to concentrate on research and development.

In early 2003 Xaar acquired the US-company Vivid Print Innovations Inc. Vivid brings Xaar an established integration team with a strong reputation for designing digital inkjet printing solutions for a wide variety of packaging, speciality graphics and industrial uses. The investment now enables to offer a 'one-stop shop' where customers can work with the Vivid team to develop bespoke or prototype printing systems from scratch using Xaar printheads.

In June 2003 Xaar introduced its first full production printhead incorporating its patented greyscale technology. The OmniDot 318 is manufactured in Japan by Xaar licensee Toshiba TEC and offers near-photographic quality printing with no compromise in speed. This product marks the next significant step forward for the industry and confirms Xaar as a market-leader in the innovation of digital inkjet printing.

Staff

Ian Dinwoodie, Chief Executive

Joined Xaar in September 2001 as Group Operations Director and was appointed Chief Executive in July 2003. With over 20 years experience in hi-tech operations, he has held a variety of roles in engineering, quality assurance and manufacturing within the semiconductor, electronics and electronic imaging industries. He most recently worked as Director of Manufacturing for Fujifilm Electronic Imaging Ltd.
Ramon Borrell, Research & Development Director

Ramon joined Xaar in August 2007. He was previously Program Manager and Technology Strategy Director in the Large Format Printing Division of Hewlett-Packard, where he spent 13 years in Barcelona, Spain, all of them in R&D. He was trained as a Mechanical Engineer and has a Master on Automotive Industry. Ramon is also Vice-President and Secretary of the Board of Directors of the Imaging Science and Technology Society.
Phil Eaves, Sales & Marketing Director

Phil joined Xaar from Dainippon Screen, a world leader in electronic equipment for the graphics arts, flat panel display, printed circuit board and semi-conductor markets, where he held the position of Marketing Manager, Europe. Phil brings over 20 years of sales and marketing expertise across many sectors of the imaging and printing industries, and has held senior management positions at Scitex, Crosfield, and Xeikon one of the pioneers of digital printing.

Contact details

316 Science Park
Cambridge
CB4 0XR
United Kingdom
Tel. +44 (0)1223 423663
Fax. +44 (0)1223 423590
Articles relating to Xaar

Just five Silicon Fen high techs hold back the stock market red ink
Will pressures of stock market reporting push Silicon Fen aristocracy towards private equity?
Xaar dives as it warns 2006 profits worse than expected
Briefs: CAT to double in size; Alizyme’s 1H08 loss narrows but sees delay in progress of key treatment
Silicon Fen Top 20, the Cambridge Cluster's own share price index, launched; will measure the collective bottom line
Briefs: NextGen raises cash; Xaar Q3 revenues lower than planned
Shires, not market professionals, wisely stirred to buy Xaar shares
Silicon Fen innovations that will soon be in a shop near you
Aveva big winner in 2006; Plasmon, Tadpole go backwards
Snippets: Xaar’s 2ic to leave; new Cambridge Uni public health research centre gets £5m
Subscribe

 

Corporate profiles

 • MedImmune Cambridge


Dr Hamish Cameron
Chief Executive and Director


Cambridge Antibody Technology (CAT), known as MedImmune as of 29 October 2007, is committed to advancing science to develop better medicines that help people live healthier, longer and more satisfying lives. In June 2006, AstraZeneca (AZ) acquired CAT, and then acquired MedImmune, Inc. in June 2007.

[MedImmune Cambridge 's profile]


Top20 Index




Currently: 71.78

Executive Webcast
Weekly interviews with executive leaders are webcast on the site’s dedicated channel.

Create Publisher Site
This Publisher Website ( slot3.siliconfenbusiness.com ) does not exist in Direct-Link-Ads.com. Please create it now.